Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Oct 4;6(10):e909. doi: 10.1038/tp.2016.179

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(a and b) Correlations between the expression levels of RGS2 in lymphoblastoid cells lines (LCLs) from 23 individual Alzheimer's disease (AD) patients (Mini Mental State Examination (MMSE) <24) and their cognitive test scores as determined at the time of blood withdrawal for LCL generation. Note that higher MMSE scores reflect better cognition, whereas it is the opposite for Alzheimer's Disease Assessment Scale (ADAS) scores (a) MMSE: a negative correlation of R=−0.555 (P=0.006) was observed (b) ADAS: a positive correlation of R=0.560 (P=0.006) was observed. Note: MMSE<24 scores were determined for 23 out of 28 AD patients (Supplementary Table 2). (c) Expression levels of RGS2 in 80 mild cognitive impairment (MCI), 104 healthy controls and 145 AD patients from whole blood (Data set GSE63060) (d–i) Expression levels of RGS2 and DLGAP1 in postmortem brains (Data set GSE5281) from AD patients and age-matched non-demented controls. (d and g) Posterior cingulate: AD (N=9) and control (N=13). (e and h) Superior frontal gyrus: AD (N=23) and control (N=11). (f and i) Medial temporal gyrus: AD (N=16) and control (N=12). (j) A scheme summarizing tentative disease-protective and disease-promoting events associated with reduced RGS2 expression in AD brain tissues. Squares on the left summarize our observations; adjacent squares summarize tentative related consquences (see the 'Discussion' section).